BRIEF-Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia

Reuters07-16

BRIEF-Quince <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia

July 16 (Reuters) - Quince Therapeutics Inc QNCX.O:

QUINCE THERAPEUTICS COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 NEAT CLINICAL TRIAL IN ATAXIA-TELANGIECTASIA
QUINCE THERAPEUTICS INC - EXPECTS NEAT TRIAL RESULTS IN Q1 2026
QUINCE THERAPEUTICS INC - PLANS NDA SUBMISSION TO FDA IN H2 2026

Source text: ID:nBw6XKDrna

Further company coverage: QNCX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2551016140?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551016140","market":"us","top_or_hot":-1,"title":"BRIEF-Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia</title></head><body><p><span>July 16 (Reuters)</span><span> - </span>Quince Therapeutics Inc <span>QNCX.O</span>:</p><ul><li><p>QUINCE THERAPEUTICS COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 NEAT CLINICAL TRIAL IN ATAXIA-TELANGIECTASIA</p></li><li><p>QUINCE THERAPEUTICS INC - EXPECTS NEAT TRIAL RESULTS IN Q1 2026</p></li><li><p>QUINCE THERAPEUTICS INC - PLANS NDA SUBMISSION TO FDA IN H2 2026</p></li></ul><p>Source text: <span>ID:nBw6XKDrna</span></p><p>Further company coverage: <span>QNCX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-16 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia</title></head><body><p><span>July 16 (Reuters)</span><span> - </span>Quince Therapeutics Inc <span>QNCX.O</span>:</p><ul><li><p>QUINCE THERAPEUTICS COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 NEAT CLINICAL TRIAL IN ATAXIA-TELANGIECTASIA</p></li><li><p>QUINCE THERAPEUTICS INC - EXPECTS NEAT TRIAL RESULTS IN Q1 2026</p></li><li><p>QUINCE THERAPEUTICS INC - PLANS NDA SUBMISSION TO FDA IN H2 2026</p></li></ul><p>Source text: <span>ID:nBw6XKDrna</span></p><p>Further company coverage: <span>QNCX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nTUA4GTKWY:1","article_id":"2551016140","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551016140","pubTimestamp":1752667602,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-TelangiectasiaJuly 16 (Reuters) - Quince Therapeutics Inc QNCX.O:QUINCE THERAPEUTICS COMPLETES ENROLLMEN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","QNCX":"Quince Therapeutics, Inc."},"translate_title":"BRIEF-Quince Therapeutics完成共济失调-毛细血管扩张症关键3期NEAT临床试验的入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNCX":0.9},"content_text":"BRIEF-Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-TelangiectasiaJuly 16 (Reuters) - Quince Therapeutics Inc QNCX.O:QUINCE THERAPEUTICS COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 NEAT CLINICAL TRIAL IN ATAXIA-TELANGIECTASIAQUINCE THERAPEUTICS INC - EXPECTS NEAT TRIAL RESULTS IN Q1 2026QUINCE THERAPEUTICS INC - PLANS NDA SUBMISSION TO FDA IN H2 2026Source text: ID:nBw6XKDrnaFurther company coverage: QNCX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551016140","isCrawlerRequest":true}